Immunology · Year 2 · from Immunology

Case 3: Adverse Event Following mRNA Vaccination

Patient Presentation

Demographics: 19-year-old male

Chief Complaint: Chest pain 4 days after second COVID-19 vaccine dose

History of Present Illness: The patient received his second dose of an mRNA COVID-19 vaccine 4 days ago. He developed chest pain yesterday that is sharp, worse with inspiration and lying flat, and improved by sitting forward. He also has low-grade fever and fatigue. He denies shortness of breath at rest.

Past Medical History:

  • No significant medical history
  • No prior cardiac disease
  • Healthy, active college athlete

Physical Examination:

  • Blood pressure: 118/72 mmHg
  • Heart rate: 88 bpm
  • Temperature: 37.6C
  • General: Mildly uncomfortable
  • Cardiac: Regular rhythm, no murmur, possible pericardial friction rub
  • Lungs: Clear

Workup and Results

Laboratory Studies:

  • Troponin I: 2.4 ng/mL (elevated, normal <0.04)
  • BNP: 180 pg/mL (mildly elevated)
  • CRP: 68 mg/L (elevated)
  • WBC: 9,800/mcL

ECG:

  • Diffuse ST elevation
  • PR depression
  • No reciprocal changes

Echocardiogram:

  • Mild left ventricular dysfunction (EF 50%)
  • Small pericardial effusion
  • No regional wall motion abnormalities

Cardiac MRI:

  • Subepicardial late gadolinium enhancement
  • Myocardial edema
  • Consistent with acute myocarditis

Clinical Image

Cardiac MRI demonstrating myocarditis with subepicardial late gadolinium enhancement (arrows) and myocardial edema, findings consistent with vaccine-associated myocarditis. Note the characteristic non-ischemic pattern.

Diagnosis

mRNA COVID-19 Vaccine-Associated Myopericarditis

Features:

  • Temporal relationship (within 7 days of dose 2)
  • Characteristic demographic (young male)
  • Typical presentation and imaging findings

Discussion

This case illustrates vaccine adverse events:

  • Myocarditis Epidemiology: The lecture notes that myocarditis following mRNA COVID-19 vaccines is most commonly reported in young males after the second dose. Incidence is approximately 1 in 50,000 in this demographic.
  • Risk-Benefit Analysis: The lecture emphasizes that the risk of myocarditis from COVID-19 infection is significantly higher than from vaccination. Most vaccine-associated myocarditis cases are mild and resolve completely.
  • Vaccine Safety Monitoring: The lecture describes passive surveillance systems (VAERS) and active surveillance that detect rare adverse events not seen in clinical trials. This allowed rapid identification of the myocarditis signal.
  • True Contraindications: The lecture distinguishes true contraindications (prior severe allergic reaction to vaccine component) from precautions. Prior myocarditis after mRNA vaccine is a precaution for future mRNA doses.

Treatment Plan

  1. Acute Management:
  • Hospital admission for monitoring
  • Telemetry
  • NSAIDs (ibuprofen) for inflammation
  • Colchicine may be added
  • Restrict physical activity
  1. Monitoring:
  • Serial troponins until trending down
  • Repeat echocardiogram before discharge
  • Cardiac MRI at 3-6 months
  1. Activity Restriction:
  • No competitive sports for 3-6 months
  • Gradual return to activity after cardiac clearance
  1. Prognosis:
  • Majority recover fully within weeks to months
  • Repeat imaging to confirm resolution
  1. Future Vaccination:
  • Counsel about precaution with future mRNA vaccines
  • Consider different vaccine platform if boosters needed
  • Discuss with cardiology

Teaching Points

  1. Vaccine-associated myocarditis is rare but most common in young males after mRNA vaccine
  2. Anaphylaxis from vaccines occurs in approximately 1 per million doses
  3. VAERS is a passive surveillance system accepting reports from anyone
  4. True vaccine contraindication is severe allergic reaction to a vaccine component
  5. Most vaccine-associated myocarditis cases are mild and resolve completely

Image Reference

For visual reference of vaccine and immunopharmacology concepts, see:

Learning Points

  1. Herd Immunity Threshold: Depends on R0; measles (R0 12-18) requires 92-95% immunity
  1. TB Screening Before TNF Inhibitors: Mandatory; TNF essential for granuloma formation
  1. Vaccine Adverse Events: Anaphylaxis ~1/million; myocarditis rare but real signal with mRNA vaccines
  1. Live Vaccine Contraindications: Immunocompromised patients, pregnancy
  1. Memory Response: Vaccines exploit immunological memory for rapid, robust response on re-exposure

All cases for this lecture as Markdown